

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
11 March 2004 (11.03.2004)

PCT

(10) International Publication Number  
**WO 2004/019904 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 9/00**

(21) International Application Number:  
PCT/US2003/026856

(22) International Filing Date: 27 August 2003 (27.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10/230,072 29 August 2002 (29.08.2002) US

(71) Applicant: **NOVADEL PHARMA INC.** [US/US]; 31  
State Highway 12, Flemington, NJ 08822 (US).

(72) Inventor: **DUGGER, Harry, A., III**; 548 Sergeantsville  
Road, Flemington, NJ 08822 (US).

(74) Agents: **POISSANT, Brian, M. et al.**; Pennie & Edmonds  
LLP, 1155 Avenue of the Americas, New York, NY 10036  
(US).

(81) Designated States (*national*): AE, AG, AI, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: **BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING ALLER-  
GIES OR ASTHMA**



(57) Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.

WO 2004/019904 A1



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING  
DRUGS FOR TREATING ALLERGIES OR ASTHMA**

**CROSS REFERENCE TO RELATED APPLICATIONS**

- 5                    This application is a continuation-in-part of application no. 09/537,118, filed March 29, 2000 which is a continuation-in-part of the U.S. national phase designation of PCT/US97/17899 filed October 1, 1997, the disclosures of which are incorporated by reference herein in their entirety.

10    **BACKGROUND OF THE INVENTION**

- It is known that certain biologically active compounds are better absorbed through the oral mucosa than through other routes of administration, such as through the stomach or intestine. However, formulations suitable for such administration by these latter routes present their own problems. For example, the biologically active compound must be compatible with the other components of the composition such as propellants, solvents, etc. Many such formulations have been proposed. For example, U.S.P. 4,689,233, Dvorsky et al., describes a soft gelatin capsule for the administration of the anti-coronary drug nifedipine dissolved in a mixture of polyether alcohols. U.S.P. 4,755,389, Jones et al., describes a hard gelatin chewable capsule containing nifedipine. A chewable gelatin capsule containing a solution or dispersion of a drug is described in U.S.P. 4,935,243, Borkan et al. U.S.P. 4,919,919, Aouda et al, and U.S.P. 5,370,862, Klokke-Bethke, describe a nitroglycerin spray for administration to the oral mucosa comprising nitroglycerin, ethanol, and other components. An orally administered pump spray is described by Cholcha in U.S.P. 5,186,925. Aerosol compositions containing a hydrocarbon propellant and a drug for administration to a mucosal surface are described in U.K. 2,082,457, Su, U.S.P. 3,155,574, Silson et al., U.S.P. 5,011,678, Wang et al., and by Parnell in U.S.P. 5,128,132. It should be noted that these references discuss bioavailability of solutions by inhalation rather than through the membranes to which they are administered.

30    **SUMMARY OF THE INVENTION**

                  A buccal aerosol spray or soft bite gelatin capsule using a polar or non-polar solvent has now been developed which provides biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect.

The buccal aerosol spray compositions of the present invention, for transmucosal administration of a pharmacologically active compound soluble in a pharmacologically acceptable non-polar solvent comprise in weight % of total composition: pharmaceutically acceptable propellant 5-80 %, nonpolar solvent 19-85 %, active compound 0.05-50 %, suitably additionally comprising, by weight of total composition a flavoring agent 0.01-10 %. Preferably the composition comprises: propellant 10-70 %, non-polar solvent 25-89.9 %, active compound 0.01-40 %, flavoring agent 1-8 %; most suitably propellant 20-70 %, non-polar solvent 25-74.75 %, active compound 0.25-35 %, flavoring agent 2-7.5 %.

The buccal polar aerosol spray compositions of the present invention, for transmucosal administration of a pharmacologically active compound soluble in a pharmacologically acceptable polar solvent are also administrable in aerosol form driven by a propellant. In this case, the composition comprises in weight % of total composition: aqueous polar solvent 10-97 %, active compound 0.1-25 %, suitably additionally comprising, by weight of total composition a flavoring agent 0.05-10 % and propellant: 2 - 10 %. Preferably the composition comprises: polar solvent 20-97 %, active compound 0.1-15%, flavoring agent 0.1-5 % and propellant 2-5 %; most suitably polar solvent 25-97 %, active compound 0.2-25 %, flavoring agent 0.1-2.5 % and propellant 2-4 %.

The buccal pump spray composition of the present invention, *i.e.*, the propellant free composition, for transmucosal administration of a pharmacologically active compound wherein said active compound is soluble in a pharmacologically acceptable non-polar solvent comprises in weight % of total composition: non-polar solvent 30-99.69 %, active compound 0.005-55 %, and suitably additionally, flavoring agent 0.1-10 %.

The buccal polar pump spray compositions of the present invention, *i.e.*, the propellant free composition, for transmucosal administration of a pharmacologically active compound soluble in a pharmacologically acceptable polar solvent comprises in weight % of total composition: aqueous polar solvent 30-99.69 %, active compound 0.001-60 %, suitably additionally comprising, by weight of total composition a flavoring agent 0.1-10 %. Preferably the composition comprises: polar solvent 37-98.58 %, active compound 0.005-55 %, flavoring agent 0.5-8 %; most suitably polar solvent 60.9-97.06 %, active compound 0.01-40 %, flavoring agent 0.75-7.5 %.

The soft bite gelatin capsules of the present invention for transmucosal administration of a pharmacologically active compound, at least partially soluble in a

pharmacologically acceptable non-polar solvent, having charged thereto a fill composition comprise in weight % of total composition: non-polar solvent 4-99.99 %, emulsifier 0-20 %, active compound 0.01-80 %, provided that said fill composition contains less than 10 % of water, suitably additionally comprising, by weight of the composition: flavoring agent 0.01-10 %. Preferably, the soft bite gelatin capsule comprises: non-polar solvent 21.5-99.975 %, emulsifier 0-15 %, active compound 0.025-70 %, flavoring agent 1-8 %; most suitably: nonpolar solvent 28.5-97.9 %, emulsifier 0-10 %, active compound 0.1-65.0 %, flavoring agent 2-6 %.

The soft bite polar gelatin capsules of the present invention for transmucosal administration of a pharmacologically active compound, at least partially soluble in a pharmacologically acceptable polar solvent, having charged thereto a composition comprising in weight % of total composition: polar solvent 25-99.89 %, emulsifier 0-20 %, active compound 0.01-65 %, provided that said composition contains less than 10 % of water, suitably additionally comprising, by weight of the composition: flavoring agent 01-10 %. Preferably, the soft bite gelatin capsule comprises: polar solvent 37-99.95 %, emulsifier 0-15 %, active compound 0.025-55 %, flavoring agent 1-8 %; most suitably: polar solvent 44-96.925 %, emulsifier 0-10 %, active compound 0.075-50 %, flavoring agent 2-6 %.

It is an object of the invention to coat the mucosal membranes either with extremely fine droplets of spray containing the active compounds or a solution or paste thereof from bite capsules.

It is also an object of the invention to administer to the oral mucosa of a mammalian in need of same, preferably man, by spray or bite capsule, a predetermined amount of a biologically active compound by this method or from a soft gelatin capsule.

A further object is a sealed aerosol spray container containing a composition of the non polar or polar aerosol spray formulation, and a metered valve suitable for releasing from said container a predetermined amount of said composition.

As the propellant evaporates after activation of the aerosol valve, a mist of fine droplets is formed which contains solvent and active compound.

The propellant is a non-Freon material, preferably a  $C_{3-8}$  hydrocarbon of a linear or branched configuration. The propellant should be substantially non-aqueous. The propellant produces a pressure in the aerosol container such that under expected normal usage it will produce sufficient pressure to expel the solvent from the container when the valve is activated but not excessive pressure such as to damage the container or valve seals.

The non-polar solvent is a non-polar hydrocarbon, preferably a C<sub>7-18</sub> hydrocarbon of a linear or branched configuration, fatty acid esters, and triglycerides, such as miglyol. The solvent must dissolve the active compound and be miscible with the propellant, *i.e.*, solvent and propellant must form a single phase at a temperature of 0-40°C  
5 a pressure range of between 1-3 atm.

The polar and non-polar aerosol spray compositions of the invention are intended to be administered from a sealed, pressurized container. Unlike a pump spray, which allows the entry of air into the container after every activation, the aerosol container of the invention is sealed at the time of manufacture. The contents of the container are  
10 released by activation of a metered valve, which does not allow entry of atmospheric gasses with each activation. Such containers are commercially available.

A further object is a pump spray container containing a composition of the pump spray formulation, and a metered valve suitable for releasing from said container a predetermined amount of said composition.

15 A further object is a soft gelatin bite capsule containing a composition of as set forth above. The formulation may be in the form of a viscous solution or paste containing the active compounds. Although solutions are preferred, paste fills may also be used where the active compound is not soluble or only partially soluble in the solvent of choice. Where water is used to form part of the paste composition, it should not exceed 10  
20 % thereof. (All percentages herein are by weight unless otherwise indicated.)

The polar or non-polar solvent is chosen such that it is compatible with the gelatin shell and the active compound. The solvent preferably dissolves the active compound. However, other components wherein the active compound is not soluble or only slightly soluble may be used and will form a paste fill.

25 Soft gelatin capsules are well known in the art. See, for example, U.S.P. 4,935,243, Borkan et al., for its teaching of such capsules. The capsules of the present invention are intended to be bitten into to release the low viscosity solution or paste therein, which will then coat the buccal mucosa with the active compounds. Typical capsules, which are swallowed whole or bitten and then swallowed, deliver the active compounds to  
30 the stomach, which results in significant lag time before maximum blood levels can be achieved or subject the compound to a large first pass effect. Because of the enhanced absorption of the compounds through the oral mucosa and no chance of a first pass effect, use of the bite capsules of the invention will eliminate much of the lag time, resulting in

hastened onset of biological effect. The shell of a soft gelatin capsule of the invention may comprise, for example: gelatin: 50-75 %, glycerin 20-30 %, colorants 0.5-1.5 %, water 5-10 %, and sorbitol 2-10 %.

5 The active compound may include, biologically active peptides, central nervous system active amines, sulfonyl ureas, antibiotics, antifungals, antivirals, sleep inducers, antiasthmatics, bronchial dilators, antiemetics, histamine H-2 receptor antagonists, barbiturates, prostaglandins and neutraceuticals.

10 The active compounds may also include antihistamines, alkaloids, hormones, benzodiazepines and narcotic analgesics. While not limited thereto, these active compounds are particularly suitable for non-polar pump spray formulation and application.

15 The active compounds may also include aldosterone antagonists, leukotriene receptor antagonists, immunomodulators and immunogens, immunosuppressants, cytokines, leukotriene receptor antagonists, mast cell mediators, eosinophil and/or mast cell antagonists, mucolytics, glucocorticoids, glycolipids, or mixtures thereof.

#### BRIEF DESCRIPTION OF THE DRAWING

FIG 1. is a schematic diagram showing routes of absorption and processing of pharmacologically active substances in a mammalian system.

#### 20 DESCRIPTION OF THE PREFERRED EMBODIMENTS

25 The preferred active compounds of the present invention are in an ionized, salt form or as the free base of the pharmaceutically acceptable salts thereof (provided, for the aerosol or pump spray compositions, they are soluble in the spray solvent). These compounds are soluble in the non-polar solvents of the invention at useful concentrations or can be prepared as pastes at useful concentrations. These concentrations may be less than the standard accepted dose for these compounds since there is enhanced absorption of the compounds through the oral mucosa. This aspect of the invention is especially important when there is a large (40-99.99%) first pass effect.

30 As propellants for the non polar sprays, propane, N-butane, iso-butane, N-pentane, iso-pentane, and neo-pentane, and mixtures thereof may be used. N-butane and iso-butane, as single gases, are the preferred propellants. It is permissible for the propellant to have a water content of no more than 0.2%, typically 0.1-0.2%. All percentages herein are by weight unless otherwise indicated. It is also preferable that the propellant be

synthetically produced to minimize the presence of contaminants which are harmful to the active compounds. These contaminants include oxidizing agents, reducing agents, Lewis acids or bases, and water. The concentration of each of these should be less than 0.1 %, except that water may be as high as 0.2%.

5                   Suitable non-polar solvents for the capsules and the non-polar sprays include (C<sub>2</sub>-C<sub>24</sub>) fatty acid (C<sub>2</sub>-C<sub>6</sub>) esters, C<sub>7</sub>-C<sub>18</sub> hydrocarbon, C<sub>2</sub>-C<sub>6</sub> alkanoyl esters, and the triglycerides of the corresponding acids. When the capsule fill is a paste, other liquid components may be used instead of the above low molecular weight solvents. These include soya oil, corn oil, other vegetable oils.

10                   As solvents for the polar capsules or sprays there may be used low molecular weight polyethyleneglycols (PEG) of 400-1000 Mw (preferably 400-600), low molecular weight (C<sub>2</sub>-C<sub>8</sub>) mono and polyols and alcohols of C<sub>7</sub>-C<sub>18</sub> linear or branch chain hydrocarbons, glycerin may also be present and water may also be used in the sprays, but only in limited amount in the capsules.

15                   It is expected that some glycerin and water used to make the gelatin shell will migrate from the shell to the fill during the curing of the shell. Likewise, there may be some migration of components from the fill to the shell during curing and even throughout the shelf-life of the capsule.

                    Therefore, the values given herein are for the compositions as prepared, it  
20   being within the scope of the invention that minor variations will occur.

                    The preferred flavoring agents are synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners (sugars, aspartame, saccharin, etc.), and combinations thereof.

                    The active substances include the active compounds selected from the group  
25   consisting of cyclosporine, sermorelin, octreotide acetate, calcitonin-salmon, insulin lispro, sumatriptan succinate, clozapine, cyclobenzaprine, dexfenfluramine hydrochloride, glyburide, zidovudine, erythromycin, ciprofloxacin, ondansetron hydrochloride, dimenhydrinate, cimetidine hydrochloride, famotidine, phenytoin sodium, phenytoin, carboprost thromethamine, carboprost, diphenhydramine hydrochloride, isoproterenol  
30   hydrochloride, terbutaline sulfate, terbutaline, theophylline, albuterol sulfate and neutraceuticals, that is to say nutrients with pharmacological action such as but not limited to carnitine, valerian, echinacea, and the like.

In another embodiment, the active compound is an aldosterone antagonist, leukotriene receptor antagonist, immunomodulator or immunogen, immunosuppressant, cytokine, leukotriene receptor antagonist, mast cell mediator, eosinophil and/or mast cell antagonist, mucolytic, glucocorticoid, glycolipid, or a mixture thereof.

5                   In one embodiment the active compound is an aldosterone antagonist. A suitable aldosterone antagonists for use in the buccal sprays of the invention includes, but is not limited to spironolactone.

                  In one embodiment the active compound is a leukotriene receptor antagonist. Suitable leukotriene receptor antagonists for use in the buccal sprays of the invention  
10 include, but are not limited to ramatroban, zariflukast, montelukast, and mixtures thereof.

                  In one embodiment the active compound is an immunomodulator or immunogen. Suitable immunomodulators or immunogens for use in the buccal sprays of the invention include, but are not limited to, interferon beta 1A, interferon beta 1B, and mixtures thereof.

15                   In one embodiment the active compound is an immunosuppressant. Suitable immunosuppressants for use in the buccal sprays of the invention include, but are not limited to, azathioprine, cyclophosphamide, cyclosporine, ERL 080, enlimomab, methotrexate, mitoxantrone, mycophenolate, mofetil, sirolimus, tacrolimus (FK-506), and mixtures thereof.

20                   In one embodiment the active compound is a cytokine. Suitable cytokines for use in the buccal sprays of the invention include, but are not limited to, darbepoetin alfa, epoetin alpha, erythropoietin, NESP, and mixtures thereof.

                  In one embodiment the active compound is a leukotriene receptor antagonist. Suitable leukotriene receptor antagonists for use in the buccal sprays of the invention  
25 include, but are not limited to, montelukast, zariflukast, ibudilast, and mixtures thereof.

                  In one embodiment the active compound is a mast cell mediator. Suitable mast cell mediators for use in the buccal sprays of the invention include, but are not limited to, ketotifen, cromolyn, and mixtures thereof.

                  In one embodiment the active compound is an eosinophil and/or mast cell  
30 antagonist. A suitable eosinophil and/or mast cell antagonists for use in the buccal sprays of the invention includes, but is not limited to nedocromil.

In one embodiment the active compound is a mucolytic. Suitable mucolytics for use in the buccal sprays of the invention include, but are not limited to, ambroxol, bromhexin, fudostein, acetylceatine, and mixtures thereof.

In one embodiment the active compound is a glucocorticoid. Suitable glucocorticoids for use in the buccal sprays of the invention include, but are not limited to, betamethasone, cortisone, dexamethasone, hydrocortisone, prednisolone, and mixtures thereof.

In one embodiment the active compound is a glycolipid. Suitable glycolipids for use in the buccal sprays of the invention include, but are not limited to imigulcerase, vancomycin, vevesca (OGT 918), and GMK vaccine.

The formulations of the present invention comprise an active compound or a pharmaceutically acceptable salt thereof. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including organic and inorganic acids or bases.

When an active compound of the present invention is acidic, salts may be prepared from pharmaceutically acceptable non-toxic bases. Salts derived from all stable forms of inorganic bases include aluminum, ammonium, calcium, copper, iron, lithium, magnesium, manganese, potassium, sodium, zinc, etc. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion-exchange resins such as arginine, betaine, caffeine, choline, N,N dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethyl-aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, isopropylamine, lysine, methyl-glucosamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, etc.

When an active compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethane-sulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric,

p-toluenesulfonic, etc. Particularly preferred are citric, hydrobromic, maleic, phosphoric, sulfuric, and tartaric acids.

5 In the discussion of methods of treatment herein, reference to the active compounds is meant to also include the pharmaceutically acceptable salts thereof. While certain formulations are set forth herein, the actual amounts to be administered to the mammal or man in need of same are to be determined by the treating physician.

The invention is further defined by reference to the following examples, which are intended to be illustrative and not limiting.

10 The following are examples of certain classes. All values unless otherwise specified are in weight percent.

EXAMPLES

## EXAMPLE 1

## Biologically active peptides including peptide hormones

A. Cyclosporine lingual spray

5		Amounts	preferred amount	most preferred amount
	cyclosporine	5-50	10-35	15-25
	water	5-20	7.5-50	9.5-12
	ethanol	5-60	7.5-50	10-20
	polyethylene glycol	20-60	30-45	35-40
10	flavors	0.1-5	1-4	2-3

B. Cyclosporine Non-Polar lingual spray

		Amounts	preferred amount	most preferred amount
	cyclosporine	1-50	3-40	5-30
15	Migylol	20	25	30-40
	Polyoxyethylated castor oil	20	25	30-40
	Butane	25-80	30-70	33-50
	flavors	0.1-5	1-4	2-3

20 C. Cyclosporine non-polar bite caosule

		Amounts	preferred amount	most preferred amount
	cyclosporine	1-35	5-25	10-20
	olive oil	25-60	35-55	30-45
25	polyoxyethylated oleic glycerides	25-60	35-55	30-45
	flavors	0.1-5	1-4	2-3

D. Cyclosporine bite capsule

		Amounts	preferred amount	most preferred amount
	cyclosporine	5-50	10-35	15-25
5	polyethylene glycol	20-60	30-45	35-40
	glycerin	5-30	7.5-25	10-20
	propylene glycol	5-30	7.5-25	10-20
	flavors	0.1-10	1-8	3-6

10 E. Sermorelin (as the acetate) lingual spray

		Amounts	preferred amount	most preferred
	sermorelin (as the acetate)	.01-5	.1-3	.2-1.0
	mannitol	1-25	5-20	10-15
	monobasic sodium phosphate,	0.1-5	1-3 1	.5-2.5
15	dibasic sodium phosphate water	0.01-5	.05-3	0.1-0.5
	ethanol	5-30	7.5-25	9.5-15
	polyethylene glycol	20-60	30-45	35-40
	propylene glycol	5-25	10-20	12-17
	flavors	0.1-5	1-4	2-3

20

F. Octreotide acetate (Sandostatin) lingual spray

		Amounts	preferred amount	most preferred amount
	octreotide acetate	0.001-0.5	0.005-0.250	0.01-0.10
	acetic acid	1-10	2-8	4-6
25	sodium acetate	1-10	2-8	4-6
	sodium chloride	3-30	.5-25	15-20
	flavors	0.1-5	0.5-.4	2-3
	ethanol	5-30	7.5-20	9.5-15
	water	15-95	35-90	65-85
30	flavors	0.1-5	1-4	2-3

G. Calcitonin-salmon lingual spray

		Amounts	preferred amount	most preferred amount
5	calcitonin-salmon	0.001-5	0.005-2	01-1.5
	ethanol	2-15	3-10	7-9.5
	water	30-95	50-90	60-80
	polyethylene glycol	2-15	3-10	7-9.5
10	sodium chloride	2.5-20	5-15	10-12.5
	flavors	0.1-5	1-4	2-3

H. Insulin lispro, lingual spray

		Amounts	preferred amount	most preferred amount
15	insulin	20-60	4-55	5-50
	glycerin	0.1-10	0.25-5	0.1-1.5
	dibasic sodium phosphate	1-15	2.5-10	4-8
	m-cresol,	1-25	5-25	7.5-12.5
	zinc oxide	0.01-0.25	.05-0.15	0.075-0.10
20	m-cresol	0.1-1	0.2-0.8	0.4-0.6
	phenol	trace amounts	trace amounts	trace amounts
	ethanol	5-20	7.5-15	9-12
	water	30-90	40-80	50-75
	propylene glycol	5-20	7.5-15	9-12
25	flavors	0.1-5	0.5-3	0.75-2
	adjust pH to 7.0-7.8 with HCl or NaOH			

## EXAMPLE 2

CNS active amines and their salts: including but not limited to tricyclic amines, GABA analogues, thiazides, phenothiazine derivatives, serotonin antagonists and serotonin reuptake inhibitors

5           A.     Sumatriptan succinate lingual spray

	Amounts	preferred amount	most preferred amount
sumatriptan succinate	0.5-30	1-20	10-15
ethanol	5-60	7.5-50	10-20
propylene glycol	5-30	7.5-20	10-15
10 polyethylene glycol	0-60	30-45	35-40
water	5-30	7.5-20	10-15
flavors	0.1-5	1-4	2-3

          B.     Sumatriptan succinate bite capsule

	Amounts	preferred amount	most preferred amount
sumatriptan succinate	0.01-5	0.05-3.5	0.075-1.75
polyethylene glycol	25-70	30-60	35-50
glycerin	25-70	30-60	35-50
flavors	0.1-10	1-8	3-6

20

          C.     Clozepine lingual spray

	Amounts	preferred amount	most preferred amount
clozepine	0.5-30	1-20	10-15
ethanol	5-60	7.5-50	10-20
25 propylene glycol	5-30	7.5-20	10-15
polyethylene glycol	0-60	30-45	35-40
water	5-30	7.5-20	10-15
flavors	0.1-5	1-4	2-3

30

D. Clozepine non-polar lingual spray with propellant

		Amounts	preferred amount	most preferred amount
	clozepine	0.5-30	1-20	10-15
5	Migylol	20-85	25-70	30-40
	Butanol	5-80	30-75	60-70
	flavors	0.1-5	1-4	2-3

E. Clozepine non-polar lingual spray without propellant

		Amounts	preferred amount	most preferred amount
	clozepine	0.5-30	1-20	10-15
	Migylol	70-99.5	80-99	85-90
	flavors	0.1-5	1-4	2-3

15 F. Cyclobenzaprine non-polar lingual spray

		Amounts	preferred amount	most preferred amount
	cyclobenzaprine (base)	0.5-30	1-20	10-15
	Migylol	20-85	25-70	30-40
	Iso-butane	15-80	30-75	60-70
20	flavors	0.1-5	1-4	2-3

G. Dexfenfluramine hydrochloride lingual spray

		Amounts	preferred amount	most preferred amount
25	dexfenfluramine Hcl	5-30	7.5-20	10-15
	ethanol	5-60	7.5-50	10-20
	propylene glycol	5-30	7.5-20	10-15
	polyethylene glycol	0-60	30-45	35-40
	water	5-30	7.5-20	10-15
30	flavors	0.1-5	1-4	2-3

## EXAMPLE 3

## Sulfonylureas

A. Glyburide lingual spray

		Amounts	preferred amount	most preferred amount
5	glyburide	0.25-25	0.5-20	0.75-15
	ethanol	5-60	-7.5-50	10-20
	propylene glycol	5-30	7.5-20	10-15
	polyethylene glycol	0-60	30-45	35-40
	water	2.5-30	5-20	6-15
10	flavors	0.1-5	1-4	2-3

B. Glyburide non-polar bite capsule

		Amounts	preferred amount	most preferred amount
	glyburide	0.01-10	0.025-7.5	0.1-4
15	olive oil	30-60	35-55	30-50
	polyoxyethylated oleic glycerides	30-60	35-55	30-50
	flavors	0.1-5	1-4	2-3

20

## EXAMPLE 4

## Antibiotics anti-fungals and anti-virals

A. Zidovudine [formerly called azidothymidine (AZT) (Retrovir)] non-polar lingual spray

5		Amounts	preferred amount	most preferred amount
	zidovudine	10-50	15-40	25-35
	Soya oil	20-85	25-70	30-40
	Butane	15-80	30-75	60-70
	flavors	0.1-5	1-4	2-3

10

B. Erythromycin bite capsule bite capsule

		Amounts	preferred amount	most preferred amount
	erythromycin	25-65	30-50	35-45
	polyoxyethylene glycol	5-70	30-60	45-55
15	glycerin	5-20	7.5-15	10-12.5
	flavors	1-10	2-8	3-6

C. Ciprofloxacin hydrochloride bite capsule

		Amounts	preferred amount	most preferred amount
20	ciprofloxacin hydrochloride	25-65	35-55	40-50
	glycerin	5-20	7.5-15	10-12.5
	polyethylene glycol	120-75	30-65	40-60
	flavors	1-10	2-8	3-6

25 D. zidovudine [formerly called azidothymidine (AZT) (Retrovir)] lingual spray

		Amounts	preferred amount	most preferred amount
	zidovudine	10-50	15-40	25-35
	water	30-80	40-75	45-70
	ethanol	5-20	7.5-15	9.5-12.5
30	polyethylene glycol	5-20	7.5-15	9.5-12.5

flavors	0.1-5	1-4	2-3
---------	-------	-----	-----

## EXAMPLE 5

## Anti-emetics

5           A.     Ondansetron hydrochloride lingual spray

		Amounts	preferred amount	most preferred amount
	ondansetron hydrochloride	1-25	2-20	2.5-15
	citric acid monohydrate	1-10	2-8	2.5-5
	sodium citrate dihydrate	0.5-5	1-4	1.25-2.5
10	water	1-90	5-85	10-75
	ethanol	5-30	7.5-20	9.5-15
	propylene glycol	5-30	7.5-20	9.5-15
	polyethylene glycol	5-30	7.5-20	9.5-15
	flavors	1-10	3-8	5-7.5

15

B.     Dimenhydrinate bite capsule

		Amounts	preferred amount	most preferred amount
	dimenhydrinate	0.5-30	2-25	3-15
	glycerin	5-20	7.5-15	10-12.5
20	polyethylene glycol	45-95	50-90	55-85
	flavors	1-10	2-8	3-6

C.     Dimenhydrinate polar lingual spray

		Amounts	preferred amount	most preferred amount
25	dimenhydrinate	3-50	4-40	5-35
	water	5-90	10-80	15-75
	ethanol	1-80	3-50	5-10
	polyethylene glycol	1-80	3-50	5-15
	sorbitol	0.1-5	0.2-40	0.4-1.0
30	aspartame	0.01-0.5	0.02-0.4	0.04-0.1

flavors	0.1-5	1-4	2-3
---------	-------	-----	-----

## EXAMPLE 6

## 5 Histamine H-2 receptor antagonists

A. Cimetidine hydrochloride bite capsule

	Amounts	preferred amount	most preferred amount
cimetidine HCl	10-60	15-55	25-50
glycerin	5-20	7.5-15	10-12.5
10 polyethylene glycol	20-90	25-85	30-75
flavors	1-10	2-8	3-6

B. Famotidine lingual spray

	Amounts	preferred amount	most preferred amount
15 famotidine	1-35	5-30	7-20
water	2.5-25	3-20	5-10
L-aspartic acid	0.1-20	1-15	5-10
polyethylene glycol	20-97	30-95	50-85
flavors	0.1-10	1-7.5	2-5

20

C. Famotidine non-polar lingual spray

	Amounts	preferred amount	most preferred amount
famotidine	1-35	5-30	7-20
Soya oil	10-50	15-40	15-20
25 Butanol	5-80	30-75	45-70
polyoxyethylated oleic glycerides	10-50	15-40	15-20
flavors	0.1-5	1-4	2-3

30

## EXAMPLE 7

## Barbiturates

A. Phenytoin sodium lingual spray

		Amounts	preferred amount	most preferred amount
5	phenytoin sodium	10-60	15-55	20-40
	water	2.5-25	3-20	5-10
	ethanol	5-30	7.5-20	9.5-15
	propylene glycol	5-30	7.5-20	9.5-15
	polyethylene glycol	5-30	7.5-20	9.5-15
10	flavors	1-10	3-8	5-7.5

B. Phenytoin non-polar lingual spray

		Amounts	preferred amount	most preferred amount
	phenytoin	5-45	10-40	15-35
15	migylol	10-50	15-40	15-20
	Butane	15-80	30-75	60-70
	polyoxyethylated oleic glycerides	10-50	15-40	15-20
	flavors	0.1-10	1-8	5-7.5

20

25

30

## EXAMPLE 8

## Prostaglandins

A. Carboprost thromethamine lingual spray

		Amounts	preferred amount	most preferred amount
5	carboprost thromethamine	0.05-5	0.1-3	0.25-2.5
	water	50-95	60-80	65-75
	ethanol	5-20	7.5-15	9.5-12.5
	polyethylene glycol	5-20	7.5-15	9.5-12.5
	sodium chloride	1-20	3-15	4-8
10	flavors	0.1-5	1-4	2-3

pH is adjusted with sodium hydroxide and/or hydrochloric acid

B. Carboprost non-polar lingual spray

		Amounts	preferred amount	most preferred amount
15	carboprost	0.05-5	0.1-3	0.25-2.5
	migylol	25-50	30-45	35-40
	Butane	5-60	10-50	20-35
20	polyoxyethylated oleic glycerides	25-50	30-45	35-40
	flavors	0.1-10	1-8	5-7.5

## EXAMPLE 9

## Neutraceuticals

A. Carnitine as bite capsule (contents are a paste)

		Amounts	preferred amount	most preferred amount
5	carnitine fumarate	6-80	30-70	45-65
	soya oil	7.5-50	10-40	12.5-35
	soya lecithin	0.001-1.0	0.005-0.5	.01-0.1
	Soya fats	7.5-50	10-40	12.5-35
	flavors	1-10	2-8	3-6

10

B. Valerian as lingual spray

		Amounts	preferred amount	most preferred amount
	valerian extract	0.1-10	0.2-7	0.25-5
	water	50-95	60-80	65-75
15	ethanol	5-20	7.5-15	9.5-12.5
	polyethylene glycol	5-20	7.5-15	9.5-12.5
	flavors	1-10	2-8	3-6

C. Echinacea as bite capsule

		Amounts	preferred amount	most preferred amount
20	echinacea extract	30-85	40-75	45-55
	soya oil	7.5-50	10-40	12.5-35
	soya lecithin	0.001-1.0	0.005-0.5	.01-0.1
	Soya fats	7.5-50	10-40	12.5-35
25	flavors	1-10	2-8	3-6

30

D. Mixtures of ingredients

		Amounts	preferred amount	most preferred amount
	magnesium oxide	15-40	20-35	25-30
	chromium picolinate	0.01-1.0	0.02-0.5	.025-0.75
5	folic acid	.025-3.0	0.05-2.0	0.25-0.5
	vitamin B-12	0.01-1.0	0.02-0.5	.025-0.75
	vitamin E	15-40	20-35	25-30
	Soya oil	10-40	12.5-35	15-20
	soya lecithin	0.1-5	0.2-4	0.5-1.5
10	soya fat	10-40	15-35	17.5-20

## EXAMPLE 10

Sleep Inducers (also CNS active amine)

A. Diphenhydramine hydrochloride lingual spray

5		Amounts	preferred amount	most preferred amount
	diphenhydramine	3-50.	4-40	5-35
	HCl water	5-90	10-80	50-75
	ethanol	1-80	3-50	5-10
	polyethylene glycol	1-80	3-50	5-15
10	Sorbitol	0.1-5	0.2-4	0.4-1.0
	aspartame	0.01-0.5	0.02-0.4	0.04-0.1
	flavors	0.1-5	1-4	2-3

## EXAMPLE 11

## Anti-Asthmatics-Bronchodilators

A. Isoproterenol Hydrochloride as polar lingual spray

		Amounts	preferred amount	most preferred amount
5	isoproterenol Hydrochloride	0.1-10	0.2-7.5	0.5-6
	water	5-90	10-80	50-75
	ethanol	1-80	3-50	5-10
	polyethylene glycol	1-80	3-50	5-15
	Sorbitol	0.1-5	0.2-4	0.4-1.0
10	aspartame	0.01-0.5	0.02-0.4	0.04-0.1
	flavors	0.1-5	1-4	2-3

B. Terbutaline sulfate as polar lingual spray

		Amounts	preferred amount	most preferred amount
15	terbutaline sulfate	0.1-10	0.2-7.5	0.5-6
	water	5-90	10-80	50-75
	ethanol	1-10	2-8	2.5-5
	Sorbitol	0.1-5	0.2-4	0.4-1.0
	aspartame	0.01-0.5	0.02-0.4	0.04-0.1
20	flavors	0.1-5	1-4	2-3

C. Terbutaline as non-polar lingual spray

		Amounts	preferred amount	most preferred amount
	terbutaline	0.1-10	0.2-7.5	0.5-6
25	migylol	25-50	30-45	35-40
	isobutane	5-60	10-50	20-35
	polyoxyethylated oleic glycerides	25-50	30-45	35-40
	flavors	0.1-10	1-8	5-7.5

30

D. Theophylline polar bite capsule

		Amounts	preferred amount	most preferred amount
	theophylline	5-50	10-40	15-30
5	polyethylene glycol	20-60	25-50	30-40
	glycerin	25-50	35-45	30-40
	propylene glycol	25-50	35-45	30-40
	flavors	0.1-5	1-4	2-3

10 E. Albuterol sulfate as polar lingual spray

		Amounts	preferred amount	most preferred amount
	albuterol sulfate	0.1-10	0.2-7.5	0.5-6
	water	5-90	10-80	50-75
	ethanol	1-10	2-8	2.5-5
15	Sorbitol	0.1-5	0.2-4	0.4-1.0
	aspartame	0.01-0.5	0.02-0.4	0.04-0.1
	flavors	0.1-5	1-4	2-3

Example 12

Polar solvent formulations using a propellant:

A. Sulfonylurea

		Amount	Preferred Amount	Most-Preferred Amount
5	glyburide	0.1-25%	0.5-15%	0.6-10%
	Ethanol	40-99%	60-97%	70-97%
	Water	0.01-5%	0.1-4%	0.2-2%
	Flavors	0.05-10%	0.1-5%	0.1-2.5%
	Propellant	2-10%	3-5%	3-4%

10

B. Prostaglandin E (vasodilator)

		Amount	Preferred Amount	Most-Preferred Amount
	prostaglandin E <sub>1</sub>	0.01-10%	0.1-5%	0.2-3%
	Ethanol	10-90%	20-75%	25-50%
15	Propylene glycol	1-90%	5-80%	10-75%
	Water	0.01-5%	0.1-4%	0.2-2%
	Flavors	0.05-10%	0.1-5%	0.1-2.5%
	Propellant	2-10%	3-5%	3-4%

20

C. Promethazine (antiemetic, sleep inducer, and CNS active amine)

		Amount	Preferred Amount	Most-Preferred Amount
	promethazine	1-25%	3-15%	5-12%
	Ethanol	10-90%	20-75%	25-50%
	Propylene glycol	1-90%	5-80%	10-75%
25	Water	0.01-5%	0.1-4%	0.2-2%
	Flavors	0.05-10%	0.1-5%	0.1-2.5%
	Propellant	2-10%	3-5%	3-4%

30

D. Meclizine

	Amount	Preferred Amount	Most-Preferred Amount
meclizine	1-25%	3-15%	5-12%
Ethanol	1-15%	2-10%	3-6
5 Propylene glycol	20-98%	5-90%	10-85%
Water	0.01-5%	0.1-4%	0.2-2%
Flavors	0.05-10%	0.1-5%	0.1-2.5%
Propellant	2-10%	3-5%	3-4%

THE CLAIMS

What is claimed is:

- 5           1.     A propellant free buccal spray composition for transmucosal administration  
of a pharmacologically active compound comprising:  
                  an active compound in an amount of between 0.001 and 60 percent by weight  
of the total composition selected from the group consisting of immunosuppressants,  
mucolytics, glucocorticoids, and mixtures thereof; and  
10               a polar solvent in an amount between 30 and 99 percent by weight of the  
total composition.
2.     The composition of claim 1, further comprising a flavoring agent in an  
amount of between 0.1 and 10 percent by weight of the total composition.
- 15           3.     The composition of claim 2, wherein the polar solvent is present in an  
amount between 37 and 98 percent by weight of the total composition, the active compound  
is present in an amount between 0.005 and 55 percent by weight of the total composition,  
and the flavoring agent is present in an amount between 0.5 and 8 percent by weight of the  
20           total composition.
4.     The composition of claim 3, wherein the polar solvent is present in an  
amount between 60 and 97 percent by weight of the total composition, the active compound  
is present in an amount between 0.01 and 40 percent by weight of the total composition, and  
25           the flavoring agent is present in an amount between 0.75 and 7.5 percent by weight of the  
total composition.
5.     The composition of claim 1, wherein the polar solvent is selected from the  
group consisting of polyethylene glycols having a molecular weight between 400 and 1000,  
30           C<sub>2</sub> to C<sub>8</sub> mono- and poly-alcohols, and C<sub>7</sub> to C<sub>18</sub> alcohols of linear or branched  
configuration.

6. The composition of claim 1, wherein the polar solvent comprises aqueous polyethylene glycol.
7. The composition of claim 1, wherein the polar solvent comprises aqueous ethanol.
8. The composition of claim 1, wherein the active compound is an immunosuppressant selected from the group consisting of azathioprine, cyclophosphamide, cyclosporine, ERL 080, enlimomab, methotrexate, mitoxantrone, mycophenolate, mofetil, sirolimus, tacrolimus (FK-506), and mixtures thereof.
9. The composition of claim 1, wherein the active compound is a mucolytic selected from the group consisting of ambroxol, bromhexin, fudostein, acetylcystine, and mixtures thereof.
10. The composition of claim 1, wherein the active compound is a glucocorticoid selected from the group consisting of betamethasone, cortisone, dexamethasone, hydrocortisone, prednisolone, and mixtures thereof.
11. The composition of claim 2, wherein the flavoring agent is selected from the group consisting of synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners, and mixtures thereof.
12. A method of administering a pharmacologically active compound to a mammal comprising spraying the oral mucosa of the mammal with the composition of claim 1.
13. The method of claim 12, wherein the amount of the spray is predetermined.
14. A buccal spray composition for transmucosal administration of a pharmacologically active compound comprising:

an active compound in an amount of between 0.1 and 25 percent by weight of the total composition selected from the group consisting of consisting of immunosuppressants, mucolytics, glucocorticoids, and mixtures thereof;

5 a polar solvent in an amount between 10 and 97 percent by weight of the total composition; and

a propellant in an amount between 2 and 10 percent by weight of the total composition, wherein said propellant is a C<sub>3</sub> to C<sub>8</sub> hydrocarbon of linear or branched configuration.

10 15. The composition of claim 14, further comprising a flavoring agent in an amount between 0.05 and 10 percent by weight of the total composition.

15 16. The composition of claim 15, wherein the polar solvent is present in an amount between 20 and 97 percent by weight of the total composition, the active compound is present in an amount between 0.1 and 15 percent by weight of the total composition, the propellant is present in an amount between 2 and 5 percent by weight of the composition, and the flavoring agent is present in an amount between 0.1 and 5 percent by weight of the total composition.

20 17. The composition of claim 16, wherein the polar solvent is present in an amount between 25 and 97 percent by weight of the total composition, the active compound is present in an amount between 0.2 and 25 percent by weight of the total composition, the propellant is present in an amount between 2 and 4 percent by weight of the composition, and flavoring agent is present in an amount between 0.1 and 2.5 percent by weight of the  
25 total composition.

18. The composition of claim 14, wherein the polar solvent is selected from the group consisting of polyethyleneglycols having a molecular weight between 400 and 1000, C<sub>2</sub> to C<sub>8</sub> mono- and poly-alcohols, and C<sub>7</sub> to C<sub>18</sub> alcohols of linear or branched  
30 configuration.

19. The composition of claim 18, wherein the polar solvent comprises aqueous polyethylene glycol.

20. The composition of claim 18, wherein the polar solvent comprises aqueous ethanol.
21. The composition of claim 14, wherein the active compound is an immunosuppressant selected from the group consisting of azathioprine, cyclophosphamide, cyclosporine, ERL 080, enlimomab, methotrexate, mitoxantrone, mycophenolate, mofetil, sirolimus, tacrolimus (FK-506), and mixtures thereof.
22. The composition of claim 14, wherein the active compound is a mucolytic selected from the group consisting of ambroxol, bromhexin, fudostein, acetylcystine, and mixtures thereof.
23. The composition of claim 14, wherein the active compound is a glucocorticoid selected from the group consisting of betamethasone, cortisone, dexamethasone, hydrocortisone, prednisolone, and mixtures thereof.
24. The composition of claim 15, wherein the flavoring agent is selected from the group consisting of synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners, and mixtures thereof.
26. The composition of claim 14, wherein the propellant is selected from the group consisting of propane, *N*-butane, *iso*-butane, *N*-pentane, *iso*-pentane, *neo*-pentane, and mixtures thereof.
27. A method of administering a pharmacologically active compound to a mammal comprising spraying the oral mucosa of the mammal with the composition of claim 14.
28. The method of claim 27, wherein the amount of the spray is predetermined.
29. A propellant free buccal spray composition for transmucosal administration of a pharmacologically active compound comprising:

- an active compound in an amount between 0.005 and 55 percent by weight of the total composition selected from the group consisting of immunosuppressants, mucolytics, glucocorticoids, and mixtures thereof; and
- a non-polar solvent in an amount between 30 and 99 percent by weight of the total composition.

30. The composition of claim 29, further comprising a flavoring agent in an amount between 0.1 and 10 percent by weight of the total composition.
31. The composition of claim 29, wherein the active compound is an immunosuppressant selected from the group consisting of azathioprine, cyclophosphamide, cyclosporine, ERL 080, enlimomab, methotrexate, mitoxantrone, mycophenolate, mofetil, sirolimus, tacrolimus (FK-506), and mixtures thereof.
32. The composition of claim 29, wherein the active compound is a mucolytic selected from the group consisting of ambroxol, bromhexin, fudostein, acetylcistine, and mixtures thereof.
33. The composition of claim 29, wherein the active compound is a glucocorticoid selected from the group consisting of betamethasone, cortisone, dexamethasone, hydrocortisone, prednisolone, and mixtures thereof.
34. The composition of claim 30, wherein the flavoring agent is selected from the group consisting of synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners, and mixtures thereof.
35. The composition of claim 29, wherein the solvent is selected from the group consisting of (C<sub>2</sub>-C<sub>24</sub>) fatty acid (C<sub>2</sub>-C<sub>6</sub>) esters, C<sub>7</sub>-C<sub>18</sub> hydrocarbons of linear or branched configuration, C<sub>2</sub>-C<sub>6</sub> alkanoyl esters, and triglycerides of C<sub>2</sub>-C<sub>6</sub> carboxylic acids.
36. The composition of claim 35, wherein the solvent is miglyol.

37. A method of administering a pharmacologically active compound to a mammal comprising spraying the oral mucosa of the mammal with the composition of claim 29.

5 38. The method of claim 37, wherein the amount of the spray is predetermined.

39. A buccal spray composition for transmucosal administration of a pharmacologically active compound comprising:

10 an active compound in an amount between 0.05 and 50 percent by weight of the total composition selected from the group consisting of immunosuppressants, mucolytics, glucocorticoids, and mixtures thereof; and

a non-polar solvent in an amount between 19 and 85 percent by weight of the total composition; and

15 a propellant in an amount between 5 and 80 percent by weight of the total composition, wherein said propellant is a C<sub>3</sub> to C<sub>8</sub> hydrocarbon of linear or branched configuration.

40. The composition of claim 39, further comprising a flavoring agent in an amount of between 0.1 and 10 percent by weight of the total composition.

20

41. The composition of claim 40, wherein the flavoring agent is selected from the group consisting of synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners, and mixtures thereof.

25 42. A buccal spray composition for transmucosal administration of a pharmacologically active compound comprising:

an active compound in an amount between 0.01 and 40 percent by weight of the total composition selected from the group consisting of immunosuppressants, mucolytics, glucocorticoids, and mixtures thereof; and

30 a non-polar solvent in an amount between 25 and 89 percent by weight of the total composition;

a propellant in an amount between 10 and 70 percent by weight of the total composition, wherein said propellant is a C<sub>3</sub> to C<sub>8</sub> hydrocarbon of linear or branched configuration; and

5 A flavoring agent is present in an amount between 1 and 8 percent by weight of the total composition.

43. The composition of claim 42, wherein the propellant is present in an amount between 20 and 70 percent by weight of the total composition, the non-polar solvent is present in an amount between 25 and 75 percent by weight of the total composition, the  
10 active compound is present in an amount from between 0.25 and 35 percent by weight of the total composition, and the flavoring agent is present in an amount between 2 and 7.5 percent by weight of the total composition.

44. The composition of claim 39, wherein the propellant is selected from the  
15 group consisting of propane, *n*-butane, *iso*-butane, *n*-pentane, *iso*-pentane, *neo*-pentane, and mixtures thereof.

45. The composition of claim 44, wherein the propellant is *n*-butane or *iso*-butane and has a water content of not more than 0.2 percent and a concentration of  
20 oxidizing agents, reducing agents, Lewis acids, and Lewis bases of less than 0.1 percent.

46. The composition of claim 39, wherein the solvent is selected from the group consisting of (C<sub>2</sub>-C<sub>24</sub>) fatty acid (C<sub>2</sub>-C<sub>6</sub>) esters, C<sub>7</sub>-C<sub>18</sub> hydrocarbons of linear or branched configuration, C<sub>2</sub>-C<sub>6</sub> alkanoyl esters, and triglycerides of C<sub>2</sub>-C<sub>6</sub> carboxylic acids.  
25

47. The composition of claim 46, wherein the solvent is miglyol.

48. The composition of claim 39, wherein the active compound is an immunosuppressant selected from the group consisting of azathioprine, cyclophosphamide,  
30 cyclosporine, ERL 080, enlimomab, methotrexate, mitoxantrone, mycophenolate, mofetil, sirolimus, tacrolimus (FK-506), and mixtures thereof.


49. The composition of claim 39, wherein the active compound is a mucolytic selected from the group consisting of ambroxol, bromhexin, fudostein, acetylceatine, and mixtures thereof.

5           50. The composition of claim 39, wherein the active compound is a glucocorticoid selected from the group consisting of betamethasone, cortisone, dexamethasone, hydrocortisone, prednisolone, and mixtures thereof.

10           51. A method of administering a pharmacologically active compound to a mammal comprising spraying the oral mucosa of the mammal with the composition of claim 39.

52. The method of claim 51, wherein the amount of the spray is predetermined.

15



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 03/26856

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K9/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 471 161 A (SCHWARZ PHARMA) 19 February 1992 (1992-02-19) claims	1-13
A	FR 2 633 933 A (EGIS GYOGYSZERGYAR) 12 January 1990 (1990-01-12) claims examples	1,5,11, 12
A	DE 33 38 978 A (BASF) 3 May 1984 (1984-05-03) claims 2,3 page 8, line 6 - line 23 examples 3,4	1-13
A	WO 99 16417 A (FLEMINGTON) 8 April 1999 (1999-04-08) claims 1-23,42,43	14-52
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

18 December 2003

Date of mailing of the international search report

30/12/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 03/26856

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 38687 A (FLEMINGTON) 23 October 1997 (1997-10-23) claims ----	39-52
A	WO 97 38663 A (FLEMINGTON) 23 October 1997 (1997-10-23) claims 1-20 ----	39-52
A	EP 0 656 206 A (SCHERING) 7 June 1995 (1995-06-07) claims -----	39-52

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 03/26856

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  

Although claims 12-13, 27-28, 37-38, 51-52 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/US 03/26856

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 471161	A	19-02-1992	DE 4026072 A1	20-02-1992
			AT 110567 T	15-09-1994
			BG 60852 B1	31-05-1996
			CS 9102099 A3	19-02-1992
			DK 471161 T3	03-10-1994
			EP 0471161 A1	19-02-1992
			ES 2060248 T3	16-11-1994
			FI 913882 A	18-02-1992
			HR 920988 A1	31-10-1996
			HU 59308 A2	28-05-1992
			IE 912509 A1	26-02-1992
			JP 2111686 C	21-11-1996
			JP 4230627 A	19-08-1992
			JP 8018981 B	28-02-1996
			PT 98658 A ,B	30-06-1992
			SI 9111215 A	31-08-1995
			SK 279132 B6	08-07-1998
			RU 2060733 C1	27-05-1996
			US 5744124 A	28-04-1998
FR 2633933	A	12-01-1990	HU 199678 B	28-03-1990
			AT 401613 B	25-10-1996
			AT 165489 A	15-03-1996
			BE 1003253 A3	11-02-1992
			CH 679371 A5	14-02-1992
			CY 1761 A	15-07-1994
			DE 3922650 A1	11-01-1990
			FR 2633933 A1	12-01-1990
			GB 2220949 A ,B	24-01-1990
			HU 9500271 A3	28-09-1995
			IT 1230742 B	29-10-1991
			JP 1925324 C	25-04-1995
			JP 2142726 A	31-05-1990
			JP 6051620 B	06-07-1994
			NL 8901751 A	01-02-1990
			SU 1837871 A3	30-08-1993
			US 5047230 A	10-09-1991
DE 3338978	A	03-05-1984	DE 3338978 A1	03-05-1984
WO 9916417	A	08-04-1999	WO 9916417 A1	08-04-1999
			AU 4894697 A	23-04-1999
			CA 2306024 A1	08-04-1999
			EP 1019019 A1	19-07-2000
			JP 2001517689 T	09-10-2001
			US 2003039680 A1	27-02-2003
			US 2003185761 A1	02-10-2003
			US 2003077227 A1	24-04-2003
			US 2003190286 A1	09-10-2003
			US 2003077228 A1	24-04-2003
			US 2003077229 A1	24-04-2003
			US 2003082107 A1	01-05-2003
			US 2003095925 A1	22-05-2003
			US 2003095926 A1	22-05-2003
			US 2003095927 A1	22-05-2003
			US 2003211047 A1	13-11-2003
WO 9738687	A	23-10-1997	US 5869082 A	09-02-1999

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/26856

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9738687	A		AT 237322 T	15-05-2003
			AU 1969397 A	07-11-1997
			CA 2251564 A1	23-10-1997
			DE 69721020 D1	22-05-2003
			DE 69721020 T2	04-12-2003
			DK 927032 T3	14-07-2003
			EP 0927032 A1	07-07-1999
			PT 927032 T	31-07-2003
			WO 9738687 A1	23-10-1997
WO 9738663	A	23-10-1997	US 5955098 A	21-09-1999
			AT 237308 T	15-05-2003
			AU 2190797 A	07-11-1997
			CA 2252050 A1	23-10-1997
			DE 69720988 D1	22-05-2003
			DE 69720988 T2	11-12-2003
			DK 904055 T3	18-08-2003
			EP 1275374 A1	15-01-2003
			EP 0904055 A2	31-03-1999
			WO 9738663 A2	23-10-1997
EP 656206	A	07-06-1995	EP 1092430 A1	18-04-2001
			EP 0656206 A1	07-06-1995
			EP 0656207 A1	07-06-1995
			GR 3037044 T3	31-01-2002
			GR 3037046 T3	31-01-2002
			AT 246497 T	15-08-2003
			AT 134509 T	15-03-1996
			AT 203901 T	15-08-2001
			AT 203902 T	15-08-2001
			AU 2017592 A	12-01-1993
			CA 2111002 A1	23-12-1992
			CN 1067578 A	06-01-1993
			CZ 9302714 A3	13-07-1994
			DE 69208660 D1	04-04-1996
			DE 69208660 T2	11-07-1996
			DE 69231992 D1	13-09-2001
			DE 69231992 T2	13-12-2001
			DE 69231994 D1	13-09-2001
			DE 69231994 T2	22-11-2001
			DE 69233150 D1	11-09-2003
			DK 588897 T3	18-03-1996
			DK 656206 T3	08-10-2001
			DK 656207 T3	08-10-2001
			EP 0518600 A1	16-12-1992
			EP 0588897 A1	30-03-1994
			ES 2084360 T3	01-05-1996
			ES 2158910 T3	16-09-2001
			ES 2158911 T3	16-09-2001
			FI 935464 A	07-12-1993
			GR 3019374 T3	30-06-1996
			HK 185596 A	11-10-1996
			HU 67449 A2	28-04-1995
			IE 921847 A1	16-12-1992
			JP 6511235 T	15-12-1994
			JP 3323199 B2	09-09-2002
			MX 9202750 A1	31-12-1992
			NO 934500 A	09-12-1993

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/26856

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 656206	A	NZ 243061 A	27-09-1993
		OA 9868 A	15-08-1994
		PT 656206 T	30-11-2001
		PT 656207 T	30-11-2001
		SK 140493 A3	05-10-1994
		WO 9222288 A1	23-12-1992
		US 5474759 A	12-12-1995
		ZA 9204164 A	24-02-1993
<hr/>			